Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

Immatics N.V.. (3/23/22). "Press Release: Immatics Announces Full Year 2021 Financial Results and Corporate Update". Tübingen & Houston, TX.

Organisations Organisation Immatics N.V. (Nasdaq: IMTX)
  Group Immatics (Group)
  Organisation 2 Bristol Myers Squibb Co. (BMS) (NYSE: BMY)
  Group Bristol Myers Squibb (BMS) (Group)
Products Product IMA203 TCR-T candidate targeting PRAME (ACTengine)
  Product 2 ACTengine® cell therapy product
  Index term 2 BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Valente, Nancy (Immatics 202203– Non-executive Board Director formerly at Genentech/Roche)

Record changed: 2022-09-05


Picture [iito] [LSE] Business Portal 650x200px

More documents for Immatics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] [LSE] Business Portal 650x300px

» top